Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The MSD Business Development & Partnering team have been shortlisted in the PraxisAuril and UK Research and Innovation (UKRI) 2019 Knowledge Exchange Awards, in the category of 'Knowledge Exchange Team of the Year'.

The Knowledge Exchange (KE) awards are a new initiative organised by PraxisAuril, the UK’s world-leading professional association for KE practitioners, to celebrate the contribution of KE professionals in enabling and facilitating the societal and economic impact of research. Sponsored by UKRI, the KE Awards recognise and celebrate the people behind the best KE achievements.

The MSD Business Development team have been shortlisted as finalists in the 'KE Team of the Year' category, which recognises a KE team who have excelled in delivering excellent service and value to their institution. Entries are judged on the success of the team including value added, relationships built, teamwork and challenges overcome. The other finalists in the category are the University of Liverpools' Consultancy Team and the University of Birminghams' Business Engagement Team.

The University of Oxford has also been shortlisted in two other categories:

The winners will be announced at the PraxisAuril conference on the evening of Thursday 13 June 2019.

 

About the MSD BUSINESS DEVELOPMENT TEAM

Over the last 8.5 years, the Business Development and Partnering Team within the Medical Sciences Division at Oxford has grown to 13 members and secured over £58M in industry investment through strategic partnerships. The team build and manage multi-year alliances with 14 companies; support major co-location initiatives with key strategic partners; foster a live pipeline of ~70 mature project development discussions, involving 35 companies and provide dedicated management of industry engagement for the NHS through close association with Oxford’s Biomedical Research Centre.

Some of the key relationships that the team have built, supported and enabled are with Novo Nordisk, Celgene, Bayer HealthCare, Elysium Health and Pfizer. Recently the introduction of a dedicated team member to develop our SME engagement strategy has been pivotal in utilising and creating new models to engage effectively with this set of unique companies.

We develop Fellowship schemes as a model for sustaining long-term engagement with international companies including UCB, Celgene, Novo Nordisk and Elysium, and have shared our experiences at international conferences. Additionally, to drive KE and networking we set up an Oxford Industry Fellows Network (over 50 Industry-sponsored Fellows and postdoctoral researchers) to offer opportunities for industry to train fellows, and for fellows to build their networks.

Our Experts in Residence scheme has driven KE in digital health (iWantGreatCare, IBM, Frog Design), surgical technologies (Koli Inc), med tech regulation (OrganOx), drug discovery and development (Evotech, GSK) and continues to grow.

As a large and disperse division with over 3000 researchers, size doesn’t always work to our advantage and can be a barrier to industry interaction. Our team successfully helps companies navigate the division and we have also found the balance between being visible, but also prioritising relationships where we can add most value.

Find out more about the MSD Business Development Team

 

 

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.